Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR). Such investors...
-
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to...
-
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of JOYY Inc. (“JOYY” or the “Company”) (NASDAQ: YY). Such investors are advised to contact...
-
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM). Such investors are...
-
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Byrna Technologies Inc. (“Byrna” or the “Company”) (NASDAQ: BYRN). Such investors are...
-
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AerCap Holdings N.V. (“AerCap” or the “Company”) (NYSE: AER). Such investors are advised...
-
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of FMC Corporation (“FMC” or the “Company”) (NYSE: FMC). Such investors are advised to...
-
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company”) (NASDAQ: APLS). Such investors...
-
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX). Such investors are advised...
-
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM). Such investors are...